NCT07793656|Not Yet RecruitingPhase 1/2DMC
mRNA Therapy to Restore Lymphatic Flow in Secondary Lymphedema
LymphARN
Loading search results
Sponsor study identifier
Secondary identifiers
CTIS
interventional
9
1 country
1
Study Start
October 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
April 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
April 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Lymphedema is a common complication of breast cancer treatment, affecting approximately a quarter of patients. Those affected can have an uncomfortable, unsightly and sometimes functionally impaired limb prone to episodes of superficial infection. The aetiology and pathophysiology of lymphedema in patients with breast cancer appear to be multifactorial and are still not fully understood.Although conservative treatment techniques can be very successful in controlling symptoms, they do not afford a cure. In this situation of unmet medical need, it is essential to find a new therapeutic solution to treat lymphedema. The approach of the LYMPHARN project is based on dual mRNA strategy delivered by FlashRNA® vector targeting both lymphatic endothelium and surrounding adipose tissue function.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 11, 2026
Actual (reported)August 28, 2026
Actual (reported)October 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
April 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
April 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Safety profile of APERNAVEC vector injection during the month following the injection
To determine the safety profile with the number, the type and the severity of adverse events) occurring
Day 1, Day 2, Day 5, Day 10 and 1 month after injection
Safety profile of APERNAVEC vector injection during 6 months following the injection
1 month, 3 months and 6 months after injection
Feasibility of the procedures
Day 0 (injection visit)
local and systemic inflammatory reaction following injections
Day 0 (post injection), Day 1, Day 2, Day 10, 1 month, 3 months and 6 months after injection
Efficacy of injections
Day 1, Day 2, Day 10, 1 month, 3 months and 6 months after injection
Pharmacokinetic of the APERNAVEC vector in the blood
Day 0, 4 hours post injection, 24h (Day 1), 48h (Day 2), Day 10 and1 month after injection
Patients with secondary lymphedema will be included to receive eight injections of the APERNAVEC (APELIN-VEGF-C FlashRNA® vector) at D0.
At day 0, the injection of APERNAVEC vector will be performed in intradermic tissue of the limb affected by lymphedema. Patient will be follow-up for 6 months
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
CHU de Toulouse
Toulouse, 31059, France
Julie MALLOIZEL-DELAUNAY, Dr
Hôpital Rangueil, CHU Toulouse
First Submitted
August 11, 2026
First Posted
August 28, 2026
Study Start
October 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
April 2028
EstimatedStudy of Lymphatic Dysfunction in Primary and Secondary Lymphedema
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
April 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 28, 2026
Record last verified: 2026-08
Study fields come from the primary record; confirmed relationships can use other sources. Selecting a record here changes its provenance and downloads, without replacing the displayed study fields.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: